Home › with Excess of Blasts Refractory Anemia
with Excess of Blasts Refractory Anemia clinical trials recruiting in the U.S.
19 studies for with Excess of Blasts Refractory Anemia are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX6 studies
- Seattle, WA5 studies
- Columbus, OH3 studies
- Boston, MA3 studies
- New York City, NY3 studies
- Washington, DC3 studies
By state
- Maryland3 studies
- Massachusetts3 studies
- New York3 studies
- North Carolina3 studies
- Ohio4 studies
- Texas7 studies
- Washington5 studies
Recently updated studies
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
RecruitingPhase 1/2
Ages 12 to 120 · All sexes · Updated Sep 30, 2026 · NCT06303193Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
RecruitingPhase 2
Ages 6 to 70 · All sexes · Updated Sep 28, 2026 · NCT01861106Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RecruitingPhase 2
Ages 4 to 80 · All sexes · Updated Sep 22, 2026 · NCT01174108Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT00801489Luspatercept + Darbepoetin in MDS
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07096297Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT03383575Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07249346Personalized NK Cell Therapy in CBT
RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Jul 30, 2026 · NCT02727803Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RecruitingPhase 2
Up to age 60 · All sexes · Updated Jun 25, 2026 · NCT03314974211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03670966MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Recruiting
Ages 0 to 25 · All sexes · Updated May 13, 2026 · NCT05794880A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
RecruitingPhase 1/2
1 Month – 25 Years · All sexes · Updated Apr 15, 2026 · NCT06839456MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RecruitingPhase 2
Up to age 60 · All sexes · Updated Apr 6, 2026 · NCT05735717A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
RecruitingPhase 2
Up to age 21 · All sexes · Updated Mar 13, 2026 · NCT04644016Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT06680752HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
RecruitingPhase 2
3 Months · All sexes · Updated Nov 12, 2025 · NCT02143830From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.